Health & Fitness
Health and Fitness
Health and Fitness
Fri, May 21, 2010
Thu, May 20, 2010 The Zacks Small-Cap Profile Features Access Pharmaceuticals and Sanofi-Aventis
CHICAGO--([ BUSINESS WIRE ])--Today, Zacks Small-Cap Institutional Research (SCIR) features Access Pharmaceuticals Inc. (OTC: [ ACCP ]) and Sanofi-Aventis (NYSE: [ SNY ]).
Zacks Small-Cap Profile
Access Pharmaceuticals Inc. poised to become a key player in the cancer/cancer supportive care market
We are initiating coverage of Access Pharmaceuticals Inc. (OTC: [ ACCP ]) with an Outperform rating. Our 12-month price target is $8 per share.
Access Pharmaceuticals, Inc. (Access) is an emerging biopharmaceutical company focused on developing a range of products primarily based upon the companya™s three key drug delivery technologies: Synthetic Polymer Targeted Drug Delivery System, Cobalamin Mediated Oral Drug Delivery System and Cobalamin Mediated Targeted Drug Delivery System.
The company currently has one approved product, MuGard, which is indicated for the management of oral mucositis, a frequent side effect for cancer patients under radiation therapy and chemotherapy. MuGard has been approved by the US, EU and South Korean health authorities. Global registration in other countries is underway.
The companya™s EU partner, SpePharm Holding, B.V. is already marketing MuGard in some European countries, and expansion into other EU countries has been planned. Access plans to officially launch MuGard in the US in third quarter of 2010. Korean partner JCOM Co., Ltd. also plans to launch MuGard in Korea soon.
We believe MuGard will strongly boost the companya™s top line in the coming quarters when the company officially launches MuGard in the third quarter of 2010. MuGard has competitive advantages over its competitors for the management of oral mucositis. Peak sales of MuGard could reach $300 million in the US alone.
We are optimistic about the companya™s pipeline, which should provide sustainable growth for years to come. Its pipeline includes two products at phase II of clinical development and several products in pre-clinical development. ProLindac is a replacement for Sanofi-Aventisa™ (NYSE: [ SNY ]) Eloxatin using the companya™s Synthetic Polymer technologies. ProLindac, representing a $3 billion plus market opportunity, is currently under phase II clinical studies for relapsed ovarian cancer.
Another phase II candidate is Thiarabine, a novel nucleoside analogue for the treatment of blood cancers and solid cancers. Other product candidates include Cobalamin-based oral therapeutics and Cobalamin-targeted therapeutics, which are in preclinical studies.
We see great potential for the companya™s three key proprietary platform technologies, which create multiple product opportunities and mitigate single product exposure. We are especially impressed with the companya™s Cobalamin-based oral delivery system. Both the oral insulin and oral human growth hormone have achieved unprecedented oral bioavailability in preclinical studies. The two products boast multi-billion blockbuster potential. Clinical studies have been planned for the two candidates.
Risks related to our call include cash burn concern, competition in the cancer market and clinical and regulatory failures.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.
Then when changes are discovered, theya™re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell, and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter Profit from the Pros. In short, ita™s your steady flow of profitable ideas GUARANTEED to be worth your time. Get your free subscription to Profit from the Pros at: [ http://at.zacks.com/?id=7171 ]
Follow us on Twitter: [ http://twitter.com/zacksresearch ]
Join us on Facebook: [ http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts ]
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
